Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dorightbythem who wrote (33702)	1/11/2016 8:12:27 AM
From: Teetime	of 63277

Roche (OTCQX:RHHBY) acquires Tensha Therapeutics for an upfront cash payment of $115M plus up to $420M in milestones. The Cambridge, MA-based firm develops cancer therapies based on innovative epigenetic technology that disrupts proteins called BET (bromodomain and extra terminal). Its lead product candidate is TEN-010, a small molecule BET inhibitor currently in Phase 1b development• BET proteins play a key role in mediating gene control and cellular memory. In cancer, they activate growth and survival genes. They also contribute to cancer cell memory by binding to the genome as molecular bookmarks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next